Article
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
The Journal of infectious diseases - 1 Jan 1999
Schapiro J M, Lawrence J, Speck R, Winters M A, Efron B, Coombs R W, Collier A C, Merigan T C
Abstract excerpt
The relationships among treatment regimens, plasma human immunodeficiency virus (HIV) RNA levels, and resistance mutations to saquinavir (codons 48 and 90) and zidovudine (codon 215) were examined in a cohort of 144 patients from the AIDS Clinical Trials Group 229 study. After 24-40 weeks of ther...
Topics
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Codon
- Cohort Studies
- Double-Blind Method
- Drug Resistance, Microbial
- Drug Therapy, Combination
- HIV Protease
- HIV-1
- Humans
- Mutation
- RNA, Viral
- Saquinavir
- Time Factors
- Zalcitabine